Theriva Biologics, Inc.
TOVX
$0.43
-$0.0102-2.32%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -14.52% | -15.76% | -18.44% | -22.82% | -10.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.48% | -15.87% | -6.47% | 3.86% | 9.10% |
| Operating Income | 19.48% | 15.87% | 6.47% | -3.86% | -9.10% |
| Income Before Tax | -21.95% | -28.33% | -28.61% | -5.17% | 6.00% |
| Income Tax Expenses | -- | -- | 76.10% | 39.89% | 25.36% |
| Earnings from Continuing Operations | -30.34% | -39.80% | -38.23% | -8.65% | 4.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.34% | -39.80% | -38.23% | -8.65% | 4.29% |
| EBIT | 19.48% | 15.87% | 6.47% | -3.86% | -9.10% |
| EBITDA | 19.52% | 15.98% | 6.64% | -3.72% | -8.93% |
| EPS Basic | 28.17% | 7.00% | -7.30% | 7.40% | 10.87% |
| Normalized Basic EPS | 59.88% | 43.17% | 21.76% | 7.65% | -1.18% |
| EPS Diluted | 28.17% | 7.00% | -7.30% | 7.40% | 10.87% |
| Normalized Diluted EPS | 59.88% | 43.17% | 21.76% | 7.65% | -1.18% |
| Average Basic Shares Outstanding | 181.70% | 109.17% | 29.89% | 14.12% | 6.13% |
| Average Diluted Shares Outstanding | 181.70% | 109.17% | 29.89% | 14.12% | 6.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |